ImmunityBio (IBRX) Total Non-Current Liabilities (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Total Non-Current Liabilities of $1.5 billion for Q1 2026, up 71.18% year-over-year from $885.2 million in Q1 2025, and up 51.37% quarter-over-quarter from $1.0 billion in Q4 2025.
ImmunityBio (IBRX) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Total Non-Current Liabilities for 13 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 71.18% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 71.18% YoY), while the FY2025 annual figure was $1.0 billion, up 14.96% from the prior year.
- Total Non-Current Liabilities grew to $1.5 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.5 billion in Q1 2026 and bottomed at $726.9 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $955.6 million across 5 years, with a median of $908.6 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 93.69% — and 2024, when it declined 20.06%.
- ImmunityBio's Total Non-Current Liabilities stood at $790.5 million in 2022, then jumped by 37.79% to $1.1 billion in 2023, then slipped by 20.06% to $870.7 million in 2024, then grew by 14.96% to $1.0 billion in 2025, then soared by 51.37% to $1.5 billion in 2026.
- Business Quant data shows IBRX's Total Non-Current Liabilities at $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 1.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Bn |
| Mar 31, 2026 | 1.52 Bn |
| Dec 31, 2025 | 1.00 Bn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 971.19 Mn |
| Mar 31, 2025 | 885.22 Mn |
| Dec 31, 2024 | 870.74 Mn |
| Sep 30, 2024 | 1.11 Bn |
| Jun 30, 2024 | 1.08 Bn |
| Mar 31, 2024 | 1.09 Bn |
| Dec 31, 2023 | 1.09 Bn |
| Sep 30, 2023 | 803.69 Mn |
| Jun 30, 2023 | 908.61 Mn |
| Mar 31, 2023 | 845.27 Mn |
| Dec 31, 2022 | 790.54 Mn |
| Sep 30, 2022 | 781.46 Mn |
| Jun 30, 2022 | 739.40 Mn |
| Mar 31, 2022 | 726.86 Mn |
| Dec 31, 2021 | 712.82 Mn |
| Sep 30, 2021 | 403.46 Mn |